Literature DB >> 19690562

Nonfunctioning pituitary adenomas: the Oxford experience.

John A H Wass1, Niki Karavitaki.   

Abstract

Nonfunctioning adenomas are the second most common type of pituitary tumor. Over the past few years, our knowledge of the epidemiology, natural history, diagnosis, treatment, and recurrence rates of these tumors has improved. Here, we highlight some of these advances and speculate on future avenues of research. In addition, we describe our own experience in the clinical management of patients with nonfunctioning adenomas. Serum prolactin levels are generally <2,000 mU/l in patients with these tumors; we propose that this level be used as the cut-off to differentiate nonfunctioning from prolactin-secreting adenomas. Despite increases in size in 19% of the microadenomas we studied, none of the patients who received no intervention developed visual complications. By contrast, 50% of untreated macroadenomas enlarged and 67% of affected patients experienced worsened or new visual-field defects. Although most recurrences develop in the first 5 years, recurrence has been reported up 14 years after surgery.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19690562     DOI: 10.1038/nrendo.2009.147

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN: 1759-5029            Impact factor:   43.330


  18 in total

1.  Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment.

Authors:  Rosario Pivonello; Carmela Matrone; Mariagiovanna Filippella; Luigi M Cavallo; Carolina Di Somma; Paolo Cappabianca; Annamaria Colao; Lucio Annunziato; Gaetano Lombardi
Journal:  J Clin Endocrinol Metab       Date:  2004-04       Impact factor: 5.958

2.  Pituitary adenomas in Sweden between 1958 and 1991: incidence, survival, and mortality.

Authors:  B Nilsson; E Gustavasson-Kadaka; B A Bengtsson; B Jonsson
Journal:  J Clin Endocrinol Metab       Date:  2000-04       Impact factor: 5.958

Review 3.  Pituitary tumours.

Authors:  J R Davis; W E Farrell; R N Clayton
Journal:  Reproduction       Date:  2001-03       Impact factor: 3.906

4.  Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma.

Authors:  Niki Karavitaki; Gaya Thanabalasingham; Helena C A Shore; Raluca Trifanescu; Olaf Ansorge; Niki Meston; Helen E Turner; John A H Wass
Journal:  Clin Endocrinol (Oxf)       Date:  2006-10       Impact factor: 3.478

5.  Risk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma.

Authors:  M Brada; D Ford; S Ashley; J M Bliss; S Crowley; M Mason; B Rajan; D Traish
Journal:  BMJ       Date:  1992-05-23

6.  Heterogeneous dopamine D2 receptor subtype messenger ribonucleic acid expression in clinically nonfunctioning pituitary adenomas.

Authors:  U Renner; T Arzberger; U Pagotto; S Leimgruber; E Uhl; A Müller; M Lange; A Weindl; G K Stalla
Journal:  J Clin Endocrinol Metab       Date:  1998-04       Impact factor: 5.958

Review 7.  Medical therapy for clinically non-functioning pituitary adenomas.

Authors:  Annamaria Colao; Carolina Di Somma; Rosario Pivonello; Antongiulio Faggiano; Gaetano Lombardi; Silvia Savastano
Journal:  Endocr Relat Cancer       Date:  2008-09-09       Impact factor: 5.678

Review 8.  The prevalence of pituitary adenomas: a systematic review.

Authors:  Shereen Ezzat; Sylvia L Asa; William T Couldwell; Charles E Barr; William E Dodge; Mary Lee Vance; Ian E McCutcheon
Journal:  Cancer       Date:  2004-08-01       Impact factor: 6.860

Review 9.  Medical therapy of pituitary adenomas: effects on tumor shrinkage.

Authors:  Annamaria Colao; Rosario Pivonello; Carolina Di Somma; Silvia Savastano; Ludovica F S Grasso; Gaetano Lombardi
Journal:  Rev Endocr Metab Disord       Date:  2009-06       Impact factor: 6.514

Review 10.  Somatostatin-dopamine ligands in the treatment of pituitary adenomas.

Authors:  Alexandru Saveanu; Philippe Jaquet
Journal:  Rev Endocr Metab Disord       Date:  2008-07-24       Impact factor: 6.514

View more
  9 in total

Review 1.  Pituitary Medicine From Discovery to Patient-Focused Outcomes.

Authors:  Shlomo Melmed
Journal:  J Clin Endocrinol Metab       Date:  2016-02-23       Impact factor: 5.958

2.  Treatment with octreotide LAR in clinically non-functioning pituitary adenoma: results from a case-control study.

Authors:  Alessandra Fusco; Antonella Giampietro; Antonio Bianchi; Vincenzo Cimino; Francesca Lugli; Serena Piacentini; Margherita Lorusso; Anna Tofani; Germano Perotti; Libero Lauriola; Carmelo Anile; Giulio Maira; Alfredo Pontecorvi; Laura De Marinis
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

3.  Role of prolactin/adenoma maximum diameter and prolactin/adenoma volume in the differential diagnosis of prolactinomas and other types of pituitary adenomas.

Authors:  Yinxing Huang; Chenyu Ding; Fangfang Zhang; Deyong Xiao; Lin Zhao; Shousen Wang
Journal:  Oncol Lett       Date:  2017-11-21       Impact factor: 2.967

4.  The prevalence of hyperprolactinemia in non-functioning pituitary macroadenomas.

Authors:  Fangfang Zhang; Yinxing Huang; Chenyu Ding; Guoliang Huang; Shousen Wang
Journal:  Int J Clin Exp Med       Date:  2015-10-15

5.  Vanishing Pituitary Macroadenoma: A Case Report.

Authors:  Emily P Sieg; Hayk Stepanyan; Russell Payne; Tao Ouyang; Brad E Zacharia
Journal:  Cureus       Date:  2016-10-20

6.  Screening and Identification of Key Microenvironment-Related Genes in Non-functioning Pituitary Adenoma.

Authors:  Jing Guo; Qiuyue Fang; Yulou Liu; Weiyan Xie; Chuzhong Li; Yazhuo Zhang
Journal:  Front Genet       Date:  2021-04-27       Impact factor: 4.599

7.  Phosphorylation of β-catenin at Serine552 correlates with invasion and recurrence of non-functioning pituitary neuroendocrine tumours.

Authors:  Pinaki Dutta; Carles Gaston-Massuet; Ashutosh Rai; Soujanya D Yelamanchi; Bishan D Radotra; Sunil K Gupta; Kanchan K Mukherjee; Manjul Tripathi; Rajesh Chhabra; Chirag K Ahuja; Narendra Kumar; Akhilesh Pandey; Márta Korbonits
Journal:  Acta Neuropathol Commun       Date:  2022-09-16       Impact factor: 7.578

8.  Whole-exome sequencing studies of nonfunctioning pituitary adenomas.

Authors:  Paul J Newey; M Andrew Nesbit; Andrew J Rimmer; Rosie A Head; Caroline M Gorvin; Moustafa Attar; Lorna Gregory; John A H Wass; David Buck; Niki Karavitaki; Ashley B Grossman; Gilean McVean; Olaf Ansorge; Rajesh V Thakker
Journal:  J Clin Endocrinol Metab       Date:  2013-02-28       Impact factor: 5.958

Review 9.  Mortality in patients with non-functioning pituitary adenoma.

Authors:  Metaxia Tampourlou; Athanasios Fountas; Georgia Ntali; Niki Karavitaki
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.